Type 1 Diabetes (Juvenile Diabetes) Pipeline Review H1 2017 report provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Additionally, the report provides an overview of key players involved in therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and features dormant and discontinued projects. Type 1 Diabetes (Juvenile Diabetes), a common complication of diabetes, is damage to the nerves that allow feeling things such as pain. Symptoms include tingling, numbness, burning and pain. The predisposing factors are obesity, hypertension, high lipid and sugar levels, smoking, etc. It may be managed by medication and dietary modification.
Type 1 Diabetes (Juvenile Diabetes) Major Companies therapeutic development reviewed Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc, Gilead Sciences Inc, Johnson & Johnson, AstraZeneca Plc, Sanofi, Merck & Co Inc, GlaxoSmithKline Plc.
Inquire for Complete PDF Report @ http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1020034 .
Description of Report:
Type 1 Diabetes (Juvenile Diabetes) Pipeline Review H1 2017 report reviews therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 3, 16 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules; respectively. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive.
Type 1 Diabetes (Juvenile Diabetes) Companies Analysed:
Adocia, AiCuris GmbH & Co KG, Alteogen Inc, Amarantus Bioscience Holdings Inc, Amarna Therapeutics BV, AntriaBio Inc, apceth Biopharma GmbH, Aphios Corp, Araim Pharmaceuticals Inc, Argos Therapeutics Inc, Astellas Pharma Inc, Athersys Inc, Atlantic Bio Sci LLC, Axxam SpA, Beta-Cell NV, Biocon Ltd, BioLineRx Ltd, BioLingus AG, Biozeus, BirchBioMed Inc, Boehringer Ingelheim GmbH, Caladrius Biosciences Inc, Cancer Prevention Pharmaceuticals Inc, Compugen Ltd, ConjuChem LLC, Daewoong Pharmaceutical Co Ltd, Dance Biopharm Inc, Denceptor Therapeutics Ltd, Diabetology (Products) Ltd, DiaMedica Therapeutics Inc, Diamyd Medical AB, Diasome Pharmaceuticals Inc, DiaVacs Inc, Dompe Farmaceutici SpA, Ensol Biosciences Inc, EpiVax Inc, Escape Therapeutics Inc, Evotec AG, Fate Therapeutics Inc, Generex Biotechnology Corp, GeNeuro SA, Geropharm LLC, Grifols SA, Hanmi Pharmaceuticals Co Ltd, Heptares Therapeutics Ltd, ImmusanT Inc, Innopharmax Inc, Intrexon Corp, Ixchel Pharma LLC, Kadimastem Ltd, Kamada Ltd, Kasiak Research Pvt Ltd, KPI Therapeutics Inc, Lexicon Pharmaceuticals Inc, Ligand Pharmaceuticals Inc, Lonestar Heart Inc, MacroGenics Inc, Medestea Research & Production SpA, MedImmune LLC, Medtronic Plc, Medy-Tox Inc, Melior Discovery Inc, Meridigen Biotech Co Ltd, Mitsubishi Tanabe Pharma Corp, Neovacs SA, Noxxon Pharma AG, Oramed Pharmaceuticals Inc, Orgenesis Inc, OSE Immunotherapeutics, Paras Biopharmaceuticals Finland Oy, Parvus Therapeutics Inc, Pathfinder Cell Therapy Inc, PharmaCyte Biotech Inc, PharmaIN Corp, Prometheon Pharma LLC, Purzer Pharmaceutical Co Ltd, RedHill Biopharma Ltd, REGiMMUNE Corp, Selecta Biosciences Inc, Semma Therapeutics Inc, Sevion Therapeutics Inc, Sotio AS, Tetragenetics Inc, Thermalin Diabetes LLC, Toleranzia AB, Transgene Biotek Ltd, Traverse Biosciences Inc, UCB SA, Unicyte AG, United Therapeutics Corp, ViaCyte Inc, XL-protein GmbH, XOMA Corp, Zealand Pharma AS, Zensun (Shanghai) Sci & Tech Co Ltd
The report provides a snapshot of the global therapeutic landscape of Type 1 Diabetes (Juvenile Diabetes). The report reviews pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) by companies and universities/research institutes based on information derived from company and industry-specific sources. The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities. The report reviews key player’s involved Type 1 Diabetes (Juvenile Diabetes) therapeutics and enlists all their major and minor projects. The report assesses Type 1 Diabetes (Juvenile Diabetes) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects. The report reviews latest news related to pipeline therapeutics for Type 1 Diabetes (Juvenile Diabetes) advantage.
Direct Purchase This Report @ http://www.reportsnreports.com/purchase.aspx?name=1020034 .
Major Table OF Content
- Type 1 Diabetes (Juvenile Diabetes) - Overview 8
- Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Development 9
- Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Assessment 37
- Type 1 Diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development 50
- Type 1 Diabetes (Juvenile Diabetes) - Drug Profiles 103
- Type 1 Diabetes (Juvenile Diabetes) - Dormant Projects 529
- Type 1 Diabetes (Juvenile Diabetes) - Discontinued Products 537
- Type 1 Diabetes (Juvenile Diabetes) - Product Development Milestones 539
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
Tel: + 1 888 391 5441
Reportnreports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision making process. Our library of 500,000+ industry & country research reports covers 5000+ micro markets. This comprehensive collection of market research reports include market share analysis, industry analysis, information on products, countries, market size, trends, business research details and much more..